


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-1.08%
+0.44%
-0.26%
-8.24%
-9.34%
MRK
Merck Company
$109.45
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Trading below its fair value
Risk Analysis

Investors losing their confidence
MRK Price Performance
$104.79 (+4.45%)
$87.49 (+25.10%)
$84.06 (+30.20%)
$89.67 (+22.06%)
MRK overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Outperform the market

Trading below its fair value
![]()
MRK Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
MRK Street Sentiment is bullish and have positive views on the near-term outlook
MRK has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
AZN
89.94
-4.75%
PFE
25.52
-0.51%
NVS
143.58
-0.53%
SNY
45.74
-1.82%
ABBV
214.04
-0.14%
What is MRK current stock price?
What are MRK stock strengths?
What is MRK Risk Level?
What is MRK market cap and volume?
What is MRK current Stock IQ?
Should I buy MRK stock right now?
Is MRK a Strong Buy right now?
What does a 'Strong Buy' rating mean for MRK?
What does a 'Strong Sell' rating mean for MRK?
What factors influence MRK's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.08%
+0.44%
-0.26%
-8.24%
-9.34%
MRK
Merck Company
Current Price
$109.45
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Trading below its fair value
Risk Analysis

Investors losing their confidence
Linked to MRK
AZN
89.94
-4.75%
PFE
25.52
-0.51%
NVS
143.58
-0.53%
SNY
45.74
-1.82%
ABBV
214.04
-0.14%

MRK Price Performance
$104.79 (+4.45%)
$87.49 (+25.10%)
$84.06 (+30.20%)
$89.67 (+22.06%)
MRK Analysts Opinion
MRK Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Outperform the market

Trading below its fair value
![]()
MRK Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
MRK Street Sentiment is bullish and have positive views on the near-term outlook
MRK has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
Today
Upgrade
Buy
BMO Capital
Jan 09, 2026
Upgrade
Outperform
Wolfe Research
Jan 08, 2026
Upgrade
Outperform
Wolfe Research
Dec 19, 2025
Upgrade
Outperform
BMO Capital
Dec 18, 2025
Price Target Raised
Outperform
BMO Capital
MRK Stock IQ
MRK Latest Analysis
Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma. MRNA) and ) on Tuesday shared median from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study of mRNA-based individualized neoantigen therapy for a serious type of skin cancer.The trial evaluated intismeran autogene (mRNA-4157 or V940) in combination with Merck’.s Keytruda (pembrolizumab) for (stage III/IV) following complete resection (removed surgically).In this pre-planned analysis adjuvant treatment with in
Tue Jan 20, 2026
Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?. Gardasils sharp sales slump in China and Japan puts Merck under pressure heading into Q4 earnings with the vaccines sales expected to stay under strain.
Tue Jan 20, 2026
Merck (MRK) Builds Post-Keytruda Growth Plan BMO Upgrades to Outperform. Merck &. Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per share BMO Capital Markets upgraded Merck &. Co. Inc. (NYSE:MRK) to Outperform on December 18 stating that the pharmaceutical company is working on a portfolio that can continue growth beyond the [….]
Tue Jan 20, 2026
Arbutus Biopharma Shares Fall 19% On European Patent Revocation . (RTTNews) - Arbutus Biopharma Corp. (ABUS) saw its stock tumble after the European Patent Office (EPO) revoked one of its key lipid nanoparticle (LNP) patents EP2279254 after years of opposition proceedings initiated by Moderna and Merck affiliates.
Fri Jan 16, 2026
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow.
Thu Jan 15, 2026
Why Mercks 32% Rally Isnt Enough to Change the Bearish View. MRK is up over 32% in three months but declining estimates Keytrudas upcoming LOE and Gardasil declines keep the stock sell-rated.
Thu Jan 15, 2026
Merck (MRK) Gains As Market Dips: What You Should Know. Merck (MRK) closed at $111.01 in the latest trading session marking a 2.54% move from the prior day.
Wed Jan 14, 2026
Dow Analyst Moves: MRK. The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average Merck is the #10 analyst pick. Merck also comes in above the median of analyst picks among the broader S&.P 500 index components c
Tue Jan 13, 2026
Is Merck & Co Inc Gaining or Losing Market Support?. ) short interest as a percent of float has fallen 12.57% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. ...
Tue Jan 13, 2026
Wall Street s Look Optimistic About Merck (MRK): Should You Buy?. The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So is it worth buying the stock?
Mon Jan 12, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.